



**FOR IMMEDIATE RELEASE**

**leon-nanodrugs supports Takeda in a feasibility assessment of leon's proprietary MicroJet Reactor (MJR®) nano-technology**

**July, 2018 | Munich, Germany**

**leon-nanodrugs GmbH ("leon") is pleased to announce that its proprietary MicroJet Reactor (MJR®) nano-technology has been selected by Takeda Pharmaceutical Company Ltd. (Takeda) for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products.**

Leon-nanodrugs announced that the company has started a feasibility assessment collaboration with Takeda. Under this collaboration, leon will support Takeda's formulation efforts to optimize solubility, bioavailability and stability for one of Takeda's current pipeline products for drug delivery using leon's proprietary nanotechnology platform –MicroJet Reactor (MJR®).

leon's platform can be used from early compound screening to production of market batches. Positive results from this feasibility study could potentially result in a long-term collaboration between the companies, and additional compounds may also be considered.

It is estimated that over 60% of pharmaceutical API's are poorly soluble in water. leon's MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR® technology is cost effective and easily scalable.

**Dr. Michael Mehler**, CEO of leon-nanodrugs GmbH comments: "We are very pleased and proud that Takeda selected our MJR® technology for a feasibility assessment with one of their compounds in development. It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide."

**About Leon:**

# leon-nanodrugs

---

## leading edge nanodrugs

**Leon-nanodrugs GmbH** (Munich) is a nanotechnology-based drug development company focused on reformulations to develop novel oral and parenteral formulations and innovative drug combinations. Build on its “network of expertise”, leon-nanodrugs can provide a 360 degree service range – from concept to product approval. By using MJR®-technology leon took the technical leadership in the re-formulation market and is creating patient benefits and economical values to existing drugs. leon works with its Pharma customers through contract development agreements, as well as co-development partnerships. leon has also initiated work on its own internal development projects, concentrating on nanotechnology-based reformulations that offer enhanced clinical and safety benefits.

[www.leon-nanodrugs.com](http://www.leon-nanodrugs.com)

Contact:

**Dr. Michael Mehler**  
**Chief Executive Officer**  
leon-nanodrugs GmbH  
Kopernikusstrasse 9  
D-81679 München  
Mail [m.mehler@leon-nanodrugs.com](mailto:m.mehler@leon-nanodrugs.com)